ELUTELUTHealthcare · Medical Devices

ELUT Stock Forecast: Elutia, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.89
+8.54% on the day

The median 12-month analyst price target for Elutia, Inc. is $5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 30 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$40.0M
Ticker Nerd rank
30/ 100
Median analyst target
$5.00
Analysts covering
1
Revenue$2.4M−61.2% y/y
Operating income−$5.9M
Net income−$7.6M
Free cash flow−$8.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+8.5%
1M
+9.7%
YTD
+28.3%
1Y
+44.6%
From 52W high
−27.1%
From 52W low
+76.1%
$0.51
$1.22
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Elutia, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
30/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
73
Issuance
73
Momentum
56
Quality
35
Revisions
33
Growth
32
Value
22
Accruals
8

Volatility (73): The share price has been relatively steady.

Accruals (8): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ELUT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ELUT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00Jan 26Apr 26Jul 26Oct 26ELUTHigh $5.00Median $5.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1
Buy
0
Hold
0
Sell
$5.00
Low
$5.00
Median
$5.00
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
10 Sept 2025Lake StreetMaintainsBuy$8.00 → $6.00
9 May 2025Lake StreetMaintainsBuy—
7 Mar 2025Cantor FitzgeraldReiteratesOverweight—
15 Nov 2024Cantor FitzgeraldReiteratesOverweight—
6 Sept 2024Cantor FitzgeraldReiteratesOverweight—
8 Aug 2024Cantor FitzgeraldMaintainsOverweight—
21 June 2024Lake StreetMaintainsBuy—
20 June 2024Cantor FitzgeraldMaintainsOverweight—
18 June 2024Cantor FitzgeraldMaintainsOverweight—
10 May 2024Cantor FitzgeraldMaintainsOverweight—
14 Nov 2023Cantor FitzgeraldMaintainsOverweight—
28 Sept 2023Lake StreetInitiatesBuy—
26 Sept 2023Cantor FitzgeraldReiteratesOverweight—
19 Sept 2023Cantor FitzgeraldReiteratesOverweight—
15 Aug 2023Cantor FitzgeraldReiteratesOverweight—
12 May 2023Cantor FitzgeraldMaintainsOverweight$12 → $10
16 Nov 2022Truist SecuritiesMaintainsBuy$8.00 → $10
15 Nov 2022Piper SandlerMaintainsOverweight$9.00 → $11
4 Mar 2022Cowen & Co.MaintainsOutperform$15 → $13
2 Nov 2020Cantor FitzgeraldInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ELUT.

Market Radar

This page is one stock. Monday covers all of them.

ELUT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ELUT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Elutia, Inc. returned +44.6% against +6.9% for the S&P 500, dividends included.

ELUT vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Jan 26Apr 26Jul 26Oct 26ELUTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ELUT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
2.9×

Cheaper than 37% of US stocks

Price / book
2.6×

Cheaper than 35% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
59.6%

Higher than 73% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−36.5%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Elutia, Inc. has a market value of $40.0M and an enterprise value of $23.9M.

  • Revenue in the twelve months to 30 June 2026: $12.1M. The latest quarter shrank 61.2% year on year.

  • Net income over the same four quarters: $51.8M, a 426.9% net margin.

  • Diluted earnings per share, trailing twelve months: $0.95.

  • Free cash flow in the twelve months to 30 June 2026: −$46.0M, after $2.0M of capital spending.

  • Shares outstanding: 44.3M.

  • Elutia, Inc. employs 25 people — $485K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

ELUT and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
ELUTElutia, Inc.$40.0M30
ECORelectroCore, Inc.$39.9M75
SRTSSensus Healthcare, Inc.$37.2M50
RPIDRapid Micro Biosystems, Inc.$36.6M36
MBOTMicrobot Medical, Inc.$45.7M15
MDAISpectral AI, Inc.$33.5M26
MYOMyomo, Inc.$32.1M62

Take a look at ELUT’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Elutia, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ELUT

What is the ELUT stock price forecast for 2026-2027?

The median 12-month analyst price target for Elutia, Inc. is $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ELUT stock a buy right now?

Of the 1 analyst covering Elutia, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Elutia, Inc. 30 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ELUT?

As at 21 Nov 2026, Elutia, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (73 of 100).

Will ELUT stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $5, and Ticker Nerd's factor model ranks Elutia, Inc. 30 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ELUT stock forecast for 2030?

No analyst covering Elutia, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELUT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $5 over the next 12 months.

How has ELUT stock performed over the past year?

Elutia, Inc. returned +44.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Elutia, Inc. do?

Elutia Inc. is a commercial-stage biomedical company focused on drug-eluting biomatrix products used in surgical reconstruction and related medical applications. Elutia’s products are designed to improve how implantable medical devices and surrounding tissue interact, with use cases in areas such as device protection, women’s health, and cardiovascular care.

Company

About Elutia, Inc.

Elutia Inc. is a commercial-stage biomedical company focused on drug-eluting biomatrix products used in surgical reconstruction and related medical applications. Elutia’s products are designed to improve how implantable medical devices and surrounding tissue interact, with use cases in areas such as device protection, women’s health, and cardiovascular care. The company offers biologic solutions intended for procedures involving implanted electronic devices, soft tissue repair, and regenerative support. Its portfolio serves healthcare providers working across specialized surgical settings where compatibility, tissue integration, and complication reduction are important. Elutia Inc. operates as a focused player in the regenerative medicine and biomaterials market, addressing needs in implant-based procedures and reconstructive care.

CEO Dr. C. Randal Mills Ph.D. · 25 employees · United States · https://elutia.com